ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Leflunomide in Children with BK Polyomavirus Viremia After Kidney Transplant

J. Hewlett1, K. Le Palma1, L. Galea1, J. Savant1, S. Lopez1, J. V. Rosano2, A. Strong1, B. Viteri1, C. LaRosa1, S. Amaral1, B. Laskin1

1The Children's Hospital of Philadelphia, Philadelphia, PA, 2Yale New Haven Health, New Haven, CT

Meeting: 2022 American Transplant Congress

Abstract number: 1357

Keywords: Infection, Kidney transplantation, Pediatric, Polyma virus

Topic: Clinical Science » Infection Disease » 26 - Kidney: Polyoma

Session Information

Session Name: Kidney: Polyoma

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Studies examining the use of leflunomide in treating BK polyomavirus (BKPyV) viremia in children after kidney transplant are limited to case reports with small numbers of patients.

*Methods: In this retrospective study we report our experience using leflunomide in 22 children with BKPyV viremia over a 10-year period. Charts were abstracted for demographic and clinical data. The primary endpoint was the proportion of patients with viremia clearance (undetectable once or below dynamic range for two consecutive blood PCRs). Secondary endpoints included the proportion of patients with a clinically significant reduction (≥0.7 log copies/mL) in viremia, time to reduction in viremia, time to viremia clearance, incidence of thrombocytopenia, transaminitis, and nephropathy leading to graft loss.

*Results: One hundred sixty-one children received a kidney transplant at our center from 2011-2021, 22 received leflunomide for BKPyV viremia. The average age of the cohort was 9.1 ± 5.7 years, 14 (64%) were male, and 10 (46%) received a living donor transplant. The indications for kidney transplant were congenital anomalies (n=15, 68%), cystic disease (n=4, 18%), or other (n=3 [2 glomerular/1 unknown], 14%). The median time to first positive viremia after transplant was 96 days [IQR, 35-147 days]. Ten patients (46%) were treated with leflunomide as first-line therapy and 12 (54%) received reduction in immunosuppression prior to initiating leflunomide. Mycophenolate was discontinued in 21 (96%) patients when leflunomide was started. Additional reductions in immunosuppression, before or after leflunomide initiation, were made at the discretion of the treating team. Viral clearance was observed in 19 (86%) patients, a median of 209 days [IQR 100-432 days] after starting leflunomide. All patients had a clinically significant reduction in viral load a median of 63 days [IQR 37-102 days] after starting leflunomide. No adverse reactions requiring discontinuation of leflunomide occurred. No patients developed thrombocytopenia. Three (14%) developed mild transaminitis. Six patients with active viremia underwent biopsy, of which 2 (33%) revealed BKPvV nephropathy. There was no graft loss.

*Conclusions: To our knowledge, this is the largest reported cohort of children treated with leflunomide after kidney transplant. Leflunomide was well tolerated. While the response rates appeared high, the time to viral clearance was prolonged and the independent effect of leflunomide may have been confounded by concomitant changes in immunosuppression.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Hewlett J, Palma KLe, Galea L, Savant J, Lopez S, Rosano JV, Strong A, Viteri B, LaRosa C, Amaral S, Laskin B. Leflunomide in Children with BK Polyomavirus Viremia After Kidney Transplant [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/leflunomide-in-children-with-bk-polyomavirus-viremia-after-kidney-transplant/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences